SBIR/STTR Research Award

DETECTION OF ALZHEIMER'S DISEASE USING A POLYMER NANOWIRE-BASED BIOSENSOR

Award identifier ad3501f9fe360619ee0396665002d0d1b0eb92753f943a1486e2e4dc4de76101Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$367,279

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INNOSENSE CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
Y45MWN6YRAB1
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): InnoSense LLC (ISL) submits this revised application with the intent of developing a cost-effective and highly sensitive polymer nanowire-based electronic biosensor (PNEBD) for the early screening of Alzheimer's disease (AD). This device is expected to have potentially significant implications in the early treatment and possible delay of debilitating symptoms associated with this disease. The Phase I project is focused on the development and verification of a high-throug hput device based on silicon photolithography processes and template-free electrodeposition of functionalized conductive polymers between narrow-gap electrode junctions. Six tasks have been proposed to establish the Phase I feasibility of detecting amyloid -a derived diffusible ligand (ADDL) antigen, a biomarker for AD, using amyloid-a (Aa) oligomer specific antibody to ADDLs. Current evidence strongly suggests a central role for amyloid-a (Aa) in the pathogenesis of AD. At the present time there is no defin ite clinical diagnosis for AD other than autopsy. It has been demonstrated that ADDLs are present at significantly elevated levels in the autopsied brain samples of humans with AD. This association of ADDLs with AD suggests that the PNEBD device could prov ide a definitive molecular basis for the laboratory diagnosis of AD. For ensuring success, a highly skilled research team, including an expert on AD, has been assembled to execute the project. Development of ultrasensitive detection methods for early scree ning of Alzheimer's disease (AD) is an important issue in clinical disease diagnosis and mechanistic understanding of Alzheimer's disease (AD). AD is a progressive neurodegenerative disease for which there is neither a cure nor an early diagnostic device. It is the leading cause of dementia in people over age 65 affecting over four million Americans. Despite its utmost importance, no ultrasensitive technologies have been developed for clinical lab diagnostic of AD. InnoSense LLC aims to fill this void by de veloping a cost-effective and highly-sensitive polymer nanowire-based electronic biosensor device (PNEBD). This device will utilize electrochemically grown polymer nanowires at micro- to nanoscale patterned electrode junctions for detecting amyloid-a deriv ed diffusible ligands (ADDLs). ADDL has been established as a biomarker for AD. The purpose of using an electrochemical method is to grow template-free, low-cost and high quality polymer nanowires on to the electrode junctions. This direct, one-step fabric ation technique is scalable. This project will advance our knowledge on the detection of Alzheimer's disease.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

141 SBIR/STTR records share this UEI (2004–2024). Reported award amounts total $58,902,557. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Energy, National Aeronautics and Space Administration, Department of Defense, Department of Health and Human Services, National Science Foundation, Environmental Protection Agency

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.